Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
| العنوان: | Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma |
|---|---|
| المؤلفون: | Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Vincent Ribrag, Charles Herbaux, Walter J. Urba, Yoshinobu Koguchi, John M. Timmerman, Caron A. Jacobson, Satyendra Suryawanshi, John E. Godwin, Ronald Levy, Roch Houot, Andrew D. Zelenetz, Cecilia Carpio, Deanne Lathers, Gilles Salles, Jaclyn Neely, Yali Liu, Radhakrishnan Ramchandren |
| المساهمون: | Institut Català de la Salut, [Timmerman J] UCLA Medical Center, Los Angeles, California. [Herbaux C] Centre Hospitalier Régional Universitaire de Lille, Lille, France. [Ribrag V] Institut Gustave Roussy, Villejuif, France. [Zelenetz AD] Memorial Sloan Kettering Cancer Center, New York, New York. [Houot R] CHU Rennes, Service Hématologie Clinique, Rennes, France. INSERM, Unité dʼInvestigation Clinique, Rennes, France. [Neelapu SS] The University of Texas MD Anderson Cancer Center, Houston, Texas. [Carpio C] Vall dʼHebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, California State University [Los Angeles] (CAL STATE LA), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Gustave Roussy (IGR), Memorial Sloane Kettering Cancer Center [New York], CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), The University of Texas M.D. Anderson Cancer Center [Houston], Indiana University System, University of Miami Leonard M. Miller School of Medicine (UMMSM), Providence Cancer Center, Hospices Civils de Lyon (HCL), Dana-Farber Cancer Institute [Boston], Universitat Autònoma de Barcelona (UAB), Bristol-Myers Squibb Company, Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Bristol-Myers SquibbBristol-Myers Squibb, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent |
| المصدر: | Scientia American Journal of Hematology American Journal of Hematology, Wiley, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩ American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩ Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Recercat. Dipósit de la Recerca de Catalunya instname |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Follicular lymphoma, Medicaments antineoplàstics - Ús terapèutic, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, immune system diseases, hemic and lymphatic diseases, Other subheadings::/therapeutic use [Other subheadings], Research Articles, biology, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Antibodies, Monoclonal, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Progression-Free Survival, 3. Good health, neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES], 030220 oncology & carcinogenesis, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, Antibody, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.drug, Research Article, medicine.medical_specialty, Cèl·lules B - Tumors - Tractament, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Refractory, [SDV.CAN] Life Sciences [q-bio]/Cancer, Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse [DISEASES], Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine, Humans, In patient, Progression-free survival, Aged, business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Lymphoma, Discontinuation, biology.protein, business, 030215 immunology |
| الوصف: | Limfoma de cèl·lules B; Urelumab Linfoma de células B; Urelumab B-cell lymphoma; Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m2 IV QW. The maximum tolerated dose (MTD) of urelumab was determined to be 0.1 mg/kg or 8 mg Q3W after a single event of potential drug-induced liver injury occurred with urelumab 0.3 mg/kg. Treatment-related AEs were reported in 52% (urelumab: grade 3/4, 15%) and 72% (urelumab + rituximab: grade 3/4, 28%); three led to discontinuation (grade 3 increased AST, grade 4 acute hepatitis [urelumab]; one death from sepsis syndrome [urelumab plus rituximab]). Objective response rates/disease control rates were 6%/19% (DLBCL, n = 31), 12%/35% (FL, n = 17), and 17%/42% (other B-cell lymphomas, n = 12) with urelumab and 10%/24% (DLBCL, n = 29) and 35%/71% (FL, n = 17) with urelumab plus rituximab. Durable remissions in heavily pretreated patients were achieved; however, many were observed at doses exceeding the MTD. These data show that urelumab alone or in combination with rituximab demonstrated manageable safety in B-cell lymphoma, but the combination did not enhance clinical activity relative to rituximab alone or other current standard of care. Research funding from Bristol-Myers Squibb, Kite/Gilead, Merck, and Spectrum Pharmaceuticals. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0361-8609 1096-8652 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29dadecdd66de9605b92ac4df56b311Test https://hdl.handle.net/11351/6523Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f29dadecdd66de9605b92ac4df56b311 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 03618609 10968652 |
|---|